Ex vivo modifiable particle or polymeric based final dosage form
First Claim
1. A final dosage form for administering a medicament to an animal, the final dosage form comprising:
- the medicament; and
a particle or polymeric material carrying the medicament in a medicament-retention state wherein the medicament is substantially not bioavailable to the animal if the final dosage form is administered to the animal,the particle or polymeric material being modifiable ex vivo by an exposure to a stimulus to carry the medicament in a medicament-release state wherein the medicament is substantially bioavailable to the animal if the final dosage form is administered to the animal.
1 Assignment
0 Petitions
Accused Products
Abstract
Provided embodiments include a final dosage form, an article of manufacture, and method. A final dosage form for administering a medicament to an animal is provided. The final dosage form includes the medicament, and a particle or polymeric material. The particle or polymeric material carries the medicament and is configured in a medicament-retention state. In medicament-retention state, the medicament is substantially not bioavailable to the animal if the final dosage form is administered to the animal. The particle or polymeric material is modifiable ex vivo by an exposure to a stimulus to a medicament-release state. In the medicament-release state, the medicament is substantially bioavailable to the animal if the final dosage form is administered to the animal.
-
Citations
43 Claims
-
1. A final dosage form for administering a medicament to an animal, the final dosage form comprising:
-
the medicament; and a particle or polymeric material carrying the medicament in a medicament-retention state wherein the medicament is substantially not bioavailable to the animal if the final dosage form is administered to the animal, the particle or polymeric material being modifiable ex vivo by an exposure to a stimulus to carry the medicament in a medicament-release state wherein the medicament is substantially bioavailable to the animal if the final dosage form is administered to the animal. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)
-
-
43. A final dosage form for administering a medicament to an animal, the final dosage form comprising:
-
the medicament; and a particle or polymeric material carrying the medicament in a medicament-retention state wherein the medicament is substantially not bioavailable to the animal if the final dosage form is administered to the animal, the particle or polymeric material being modifiable ex vivo by an exposure to a first stimulus to carry the medicament in a first medicament-release state wherein the medicament has a first bioavailability to the animal if the final dosage form is administered to the animal, and the particle or polymeric material being modifiable ex vivo by an exposure to a second stimulus to a second medicament-release state, wherein the medicament has a second bioavailability to the animal if the final dosage form is administered to the animal.
-
Specification